ProShare Advisors
VERV

ProShare Advisors’s Verve Therapeutics VERV Stock Holding History

ProShare Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,787
Closed -$492K – 2119
2025
Q2 		$492K Buy
43,787
+24,403
+126% +$139K ﹤0.01% 1140
2025
Q1 		$88.6K Sell
19,384
-4,632
-19% -$31K ﹤0.01% 1863
2024
Q4 		$135K Buy
24,016
+5,592
+30% +$31.5K ﹤0.01% 2002
2024
Q3 		$89.2K Buy
18,424
+4,417
+32% +$25.7K ﹤0.01% 1901
2024
Q2 		$68.4K Sell
14,007
-3,689
-21% -$23.2K ﹤0.01% 1712
2024
Q1 		$235K Buy
17,696
+4,184
+31% +$55.5K ﹤0.01% 1579
2023
Q4 		$188K Buy
13,512
+2,755
+26% +$34.1K ﹤0.01% 1654
2023
Q3 		$143K Buy
10,757
+152
+1% +$2.45K ﹤0.01% 1562
2023
Q2 		$199K Buy
+10,605
New +$177K ﹤0.01% 1547
2023
Q1 		– Sell
-11,112
Closed -$215K – 1912
2022
Q4 		$215K Buy
11,112
+1,053
+10% +$27.9K ﹤0.01% 1451
2022
Q3 		$345K Buy
+10,059
New +$321K ﹤0.01% 1067
2022
Q2 		– Sell
-11,817
Closed -$270K – 2136
2022
Q1 		$270K Buy
11,817
+1,595
+16% +$45.6K ﹤0.01% 1699
2021
Q4 		$377K Buy
+10,222
New +$429K ﹤0.01% 1645

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

ProShare Advisors's VERV Position: Q3 2025 in Review

ProShare Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 43,787 shares — an estimated $492K sold.

ProShare Advisors first reported a position in VERV in Q4 2021 and held it in 13 quarters. The position peaked at $492K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • ProShare Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ProShare Advisors sold 43,787 Verve Therapeutics shares in Q3 2025, an estimated $492K.
  • ProShare Advisors first reported a position in Verve Therapeutics in Q4 2021 and held it in 13 quarters.
  • ProShare Advisors's Verve Therapeutics position peaked at $492K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.